Iovance Biotherapeutics Inc Stock Research

Market Summary

USD5.78-0.15

Market Closed

-2.53%

IOVA Stock Price

IOVA RSI Chart

IOVA Valuation

Market Cap

1.1B

Price/Earnings (Trailing)

-2.74

Price/Free Cashflow

-3.47

IOVA Price/Sales (Trailing)

IOVA Profitability

Return on Equity

-79.24%

Return on Assets

-59.62%

Free Cashflow Yield

-28.85%

IOVA Fundamentals

IOVA Revenue

IOVA Earnings

Earnings (TTM)

-395.9M

Earnings Y/Y

-6.03%

Earnings Q/Q

-5.72%

Price Action

52 Week Range

5.4218.73

(Low)(High)

Last 7 days

-12.7%

Last 30 days

-17.8%

Last 90 days

-5.6%

Trailing 12 Months

-65.1%

IOVA Financial Health

Current Ratio

5.24

IOVA Investor Care

Shares Dilution (1Y)

19.62%

Diluted EPS (TTM)

-2.49

Peers (Alternatives to Iovance Biotherapeutics)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
AMGN	124.2B	26.3B	-2.34%	1.62%	18.96	4.72	1.32%	11.18%
GILD	98.0B	27.3B	-7.18%	37.83%	21.33	3.59	-0.09%	-26.23%
MRNA	57.1B	19.3B	-7.28%	-16.95%	6.83	2.97	4.29%	-31.47%
BIIB	38.1B	10.2B	-3.01%	25.82%	12.5	3.74	-7.36%	95.80%
MID-CAP
NBIX	9.2B	1.5B	-6.54%	2.94%	59.61	6.19	31.34%	72.43%
DNLI	3.1B	108.5M	-20.63%	-31.77%	-9.51	28.59	122.90%	-12.19%
BEAM	2.2B	60.9M	-22.54%	-46.32%	-7.52	35.66	17.51%	22.00%
BBIO	1.9B	107.9M	7.80%	19.42%	-3.99	17.93	54.84%	17.36%
SMALL-CAP
RCUS	1.2B	112.0M	-12.49%	-50.70%	-4.44	10.58	-70.76%	-603.77%
REPL	1.1B	7.0M	-19.12%	19.58%	-7.01	156.87	131.81%	-45.39%
IOVA	1.1B	-	-17.78%	-65.10%	-2.74	-	-	-15.67%
NVAX	499.9M	2.0B	-38.13%	-92.75%	-0.76	0.25	72.89%	62.27%
VXRT	98.0M	107.0K	-22.42%	-85.54%	-0.91	915.57	-88.00%	-52.91%
IBIO	26.6M	-	29.52%	-80.89%	-0.33	3.21	0.51%	-185.61%
XBIO	6.0M	1.6M	-24.22%	-53.86%	-0.87	3.87	165.64%	-38.13%

Financials for Iovance Biotherapeutics

Income Statement (Last 12 Months)
Description	(%) Q/Q	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1
Revenue	NaN%
Interest Expenses	-	0.00	-	-	-	-

Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Assets	21.6%	664	546	611	701	777
Current Assets	29.5%	479	370	432	490	508
Cash Equivalents	95.8%	232	118	108	92.00	78.00
Net PPE	4.5%	105	101	101	103	101
Liabilities	8.0%	164	152	138	149	156
Current Liabilities	15.4%	91.00	79.00	64.00	77.00	89.00
Shareholder's Equity	26.9%	500	394	473	552	622
Retained Earnings	-7.2%	-1,568	-1,463	-1,363	-1,264	-1,172
Additional Paid-In Capital	11.3%	2,069	1,859	1,839	1,818	1,795
Shares Outstanding	19.0%	188	158	158	157	157

Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Cashflow From Operations	-8.9%	-292	-268	-262	-239	-227
Share Based Compensation	0.5%	84.00	84.00	83.00	75.00	70.00
Cashflow From Investing	-21.2%	256	325	264	9.00	0.00
Cashflow From Financing	5004.7%	190	4.00	24.00	190	239

Risks for IOVA

What is the probability of a big loss on IOVA?

100%

Probability that Iovance Biotherapeutics stock will be more than 20% underwater in next one year

90.8%

Probability that Iovance Biotherapeutics stock will be more than 30% underwater in next one year.

79.2%

Probability that Iovance Biotherapeutics stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does IOVA drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Iovance Biotherapeutics was unfortunately bought at previous high price.

Drawdowns

Returns for IOVA

Cumulative Returns on IOVA

-0.4%

10-Year Cumulative Returns

3.4%

7-Year Cumulative Returns

-19.5%

5-Year Cumulative Returns

-37.6%

3-Year Cumulative Returns

What are the long-term rolling returns for IOVA?

FIve years rolling returns for Iovance Biotherapeutics.

Annualized Returns

Which funds bought or sold IOVA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-03-10	VICTORY CAPITAL MANAGEMENT INC	reduced	-69.97	-1,093,090	273,907	-%
2023-03-06	Rockefeller Capital Management L.P.	added	11.34	-76,000	219,000	-%
2023-02-28	Voya Investment Management LLC	unchanged	-	-618,494	1,239,510	-%
2023-02-24	NATIXIS	new	-	6,646	6,646	-%
2023-02-22	TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY	sold off	-100	-821,000	-	-%
2023-02-21	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	unchanged	-	-5,987	12,013	-%
2023-02-21	MACQUARIE GROUP LTD	reduced	-11.51	-273,000	361,000	-%
2023-02-16	CHARTWELL INVESTMENT PARTNERS, LLC	sold off	-100	-447,000	-	-%
2023-02-15	ATLAS CAPITAL ADVISORS LLC	sold off	-100	-9,101	-	-%
2023-02-15	JANE STREET GROUP, LLC	added	67.58	68,262	651,262	-%

Latest Funds Activity

Are funds buying IOVA calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own IOVA

No. of Funds

Iovance Biotherapeutics News

Schedule 13G FIlings of Iovance Biotherapeutics

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 17, 2023	point72 asset management, l.p.	4.6%	7,347,600	SC 13G
Feb 14, 2023	avoro capital advisors llc	4.4%	7,020,000	SC 13G/A
Feb 14, 2023	perceptive advisors llc	6.3%	9,971,780	SC 13G/A
Feb 09, 2023	vanguard group inc	9.16%	14,463,082	SC 13G/A
Feb 06, 2023	wellington management group llp	0.27%	421,610	SC 13G/A
Feb 03, 2023	blackrock inc.	7.7%	12,076,276	SC 13G
Feb 02, 2023	state street corp	9.32%	14,715,475	SC 13G
Jan 13, 2023	quogue capital llc	12.52%	2e+07	SC 13D/A
Dec 30, 2022	mhr fund management llc	5.8%	10,511,920	SC 13G
Feb 24, 2022	blackrock inc.	4.7%	7,408,505	SC 13G/A

IOVA Fair Value

Recent SEC filings of Iovance Biotherapeutics

View All Filings

Date Filed	Form Type	Document
Mar 10, 2023	8-K	Current Report
Mar 06, 2023	4	Insider Trading
Mar 06, 2023	4	Insider Trading
Mar 06, 2023	4	Insider Trading
Mar 06, 2023	4	Insider Trading
Feb 28, 2023	10-K	Annual Report
Feb 28, 2023	8-K	Current Report
Feb 17, 2023	SC 13G	Major Ownership Report
Feb 14, 2023	SC 13G/A	Major Ownership Report
Feb 14, 2023	SC 13G/A	Major Ownership Report

Latest Insider Trading transactions for IOVA

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-01-17	BILINSKY IGOR	sold (taxes)	-30,034	6.43	-4,671	chief operating officer
2023-01-17	BILINSKY IGOR	acquired	-	-	11,248	chief operating officer
2023-01-17	Vogt Frederick G	acquired	-	-	83,325	interim ceo & general counsel
2023-01-17	GRAF FINCKENSTEIN FRIEDRICH	sold (taxes)	-30,079	6.43	-4,678	chief medical officer
2023-01-17	GRAF FINCKENSTEIN FRIEDRICH	acquired	-	-	11,248	chief medical officer
2023-01-17	Vogt Frederick G	sold (taxes)	-234,316	6.43	-36,441	interim ceo & general counsel
2023-01-03	BILINSKY IGOR	sold (taxes)	-64,478	6.11	-10,553	chief operating officer
2023-01-03	BILINSKY IGOR	acquired	-	-	18,850	chief operating officer
2023-01-03	Bellemin Jean-Marc	acquired	-	-	18,850	chief financial officer
2023-01-03	Bellemin Jean-Marc	sold (taxes)	-64,478	6.11	-10,553	chief financial officer

About Iovance Biotherapeutics

Frederick G. Vogt

www.lionbio.com

320

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'UniversitÃƒÂ© de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

IOVA Income Statement

2022-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Costs and expenses
Research and development	$ 294,781	$ 259,039	$ 201,727
General and administrative	104,097	83,664	60,210
Total costs and expenses	398,878	342,703	261,937
Loss from operations	(398,878)	(342,703)	(261,937)
Other income
Interest income, net	2,985	451	2,356
Net Loss	$ (395,893)	$ (342,252)	$ (259,581)
Net Loss Per Share of Common Stock, Basic	$ (2.49)	$ (2.23)	$ (1.88)
Net Loss Per Share of Common Stock, Diluted	$ (2.49)	$ (2.23)	$ (1.88)
Weighted Average Shares of Common Stock Outstanding, Basic	159,259	153,406	138,301
Weighted Average Shares of Common Stock Outstanding, Diluted	159,259	153,406	138,301

IOVA Balance Sheet

2022-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current Assets
Cash and cash equivalents	$ 231,731	$ 78,229
Short-term investments	240,114	426,181
Prepaid expenses and other assets	7,271	3,546
Total Current Assets	479,116	507,956
Property and equipment, net	105,232	100,938
Operating lease right-of-use assets	73,015	68,983
Long-term investments		91,588
Restricted cash	6,430	6,084
Long-term assets	189	1,784
Total Assets	663,982	777,333
Current Liabilities
Accounts payable	26,603	27,377
Accrued expenses	52,295	56,766
Operating lease liabilities	12,587	5,057
Total Current Liabilities	91,485	89,200
Non-Current Liabilities
Operating lease liabilities - non-current	71,859	65,474
Long-term note payable	1,000	1,000
Total Non-Current Liabilities	72,859	66,474
Total Liabilities	164,344	155,674
Commitments and contingencies
Stockholders' Equity
Common stock, $0.000041666 par value; 300,000,000 shares authorized, 187,812,072 and 157,004,742 shares issued and outstanding as of December 31, 2022 and December 31, 2021, respectively	8	7
Accumulated other comprehensive loss	(902)	(601)
Additional paid-in capital	2,068,867	1,794,695
Accumulated deficit	(1,568,338)	(1,172,445)
Total Stockholders' Equity	499,638	621,659
Total Liabilities and Stockholders' Equity	663,982	777,333
Series A Convertible Preferred Stock
Stockholders' Equity
Preferred stock, Value	0	0
Series B Convertible Preferred Stock
Stockholders' Equity
Preferred stock, Value	$ 3	$ 3